February 1, 2019

Hypertension (high blood pressure) affects between 30-40 percent of adults throughout the world.

While many adults can regulate their high blood pressure with medication and lifestyle changes, there are some challenges in controlling blood pressure due to poor medication adherence. For those patients, a different approach to combat high blood pressure may be necessary.

The CAMC Clinical Trials Center, through its innovative medical research, recently offered a clinical study of an investigational treatment called renal denervation for individuals with high blood pressure.


SpyralHTN%20Clinical%20Trial%20Picture%20for%20story.png

Pictured: Aravinda Nanjundappa, MD, Briana Knapp, Mariah Preast, Alicia Pekar, James Campbell, MD, Christina Bethea, Megan Atkins


CAMC is the first site participating in this trial in West Virginia and enrolled its first patient in November.

One way high blood pressure can occur is when the renal nerves that control the kidneys become over-active, thereby causing the blood pressure to rise. The Spyral HTN clinical trial program focuses on a potential way to reduce blood pressure and potentially limit damage to the patient’s heart, kidney and blood vessels through an investigational procedure known as renal denervation.

“The Spyral HTN medical study for hypertension is a unique study to evaluate the role of renal denervation in patients with mild to moderate hypertension,” said Aravinda Nanjundappa, MD, interventional cardiologist.

This investigational procedure uses the Symplicity Spyral™ catheter, which is inserted in the groin area through a small tube. Imaging is then used to advance the catheter through the tube. The catheter stops at multiple locations in the artery to adjust the renal nerves with radio frequency in order to help disrupt and balance the overactive signaling that is being sent to and from the kidneys.

This innovative therapy is a minimally-invasive procedure that can be performed in a single session. Patients who are eligible for this trial undergo multiple screening tests and follow-up appointments with the study doctor to help determine the safety and efficacy of the procedure.

“We in West Virginia have a high rate of hypertension and cardiovascular disease burden compared to the rest of the United States,” Nanjundappa said. “An innovative treatment option such as renal denervation has the potential to be a game changer in patient care.”

The CAMC Clinical Trials Center is currently recruiting for the Spyral HTN clinical trial program. If interested, call (304) 388-9944. Visit the CAMC Clinical Trials Center online to learn more about this and other trials.

CAUTION: Investigational device. Limited by federal (U.S.) law to investigational use.

Back to Search